LIFECORE BIOMEDICAL, INC. Net Cash Provided by (Used in) Continuing Operations
LIFECORE BIOMEDICAL, INC. (LFCR) reported Net Cash Provided by (Used in) Continuing Operations of -$5.71 million for the 3-month period ending 2014-08-31, per its 10-Q filed 2014-10-08.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2014-10-08
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) continuing operations for the quarter ending 2014-08-31 was -$5.71M.
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) continuing operations for the quarter ending 2013-08-25 was -$4.82M.
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) continuing operations for fiscal 2014 was $525.00K.
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) continuing operations for fiscal 2013 was -$8.46M, a 160.24% decline from fiscal 2012.
- LIFECORE BIOMEDICAL, INC. net cash provided by (used in) continuing operations for fiscal 2012 was $14.04M.
| Period end | Net Cash Provided by (Used in) Continuing Operations 3 month | Net Cash Provided by (Used in) Continuing Operations 12 month |
|---|---|---|
| 2014-08-31 | -$5.71M 10-Q · filed 2014-10-08 | |
| 2014-05-25 | $525.00K 10-K · filed 2014-08-01 | |
| 2013-08-25 | -$4.82M 10-Q · filed 2014-10-08 | |
| 2013-05-26 | -$8.46M 10-K · filed 2014-08-01 | |
| 2012-05-27 | $14.04M 10-K · filed 2014-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |